newwin
Luciann Nguyen
Settings
← Accounts
biotech

Jian Li

52
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Jian Li

New trial — JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

New trialNCT06838338
52/100
Opportunity
Commercial fit11/25
Clinical timing19/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1 trial NCT06838338 posted by Jian Li: "JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC". New trial on a phase 1 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 243 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT06838338
JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC
phase 1
mol. elig.